MB710 |
| Catalog No.GC62629 |
Le MB710, un dérivé de l'aminobenzothiazole, est un stabilisateur de la mutation p53 oncogène Y220C. MB710 se lie étroitement À la poche Y220C et stabilise p53-Y220C, avec un Kd de 4,1 μM. MB710 montre une activité anticancéreuse dans les lignées cellulaires p53-Y220C.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2230044-57-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1?μM. MB710 shows anticancer activity in p53-Y220C cell lines[1].
MB710 (0-200 μM; 72 hours) shows relatively low toxicity against all cell lines tested at concentrations up to 60?μM, while showing initial selective viability reduction at higher concentrations[1].MB710 (72 hours) treats cancer cell lines NUGC3, NUGC4, WI38 and SW1088, with IC50s of 90, 120, >120, >120 μM, respectively[1].MB710 (0-120 μM; 72 hours; HUH-7 cells) shows stronger cytotoxic effects in presence of p53-Y220C[1].
[1]. Baud MGJ, et al. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem. 2018;152:101-114.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *